amlitelimab

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

Sanofi slumps despite positive eczema drug readout

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

News

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

News

AAD: Sanofi showcases data on possible Dupixent successor

Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2

News

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi slumps despite positive eczema drug readout

Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma

AAD: Sanofi showcases data on possible Dupixent successor

Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e...

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

amlitelimab

Editor's Picks